175 related articles for article (PubMed ID: 23300967)
1. Gleevec, an Abl family inhibitor, produces a profound change in cell shape and migration.
Chen Z; Lessey E; Berginski ME; Cao L; Li J; Trepat X; Itano M; Gomez SM; Kapustina M; Huang C; Burridge K; Truskey G; Jacobson K
PLoS One; 2013; 8(1):e52233. PubMed ID: 23300967
[TBL] [Abstract][Full Text] [Related]
2. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.
Lin YL; Roux B
J Am Chem Soc; 2013 Oct; 135(39):14741-53. PubMed ID: 24001034
[TBL] [Abstract][Full Text] [Related]
3. Gleevec target Abl important for normal immune activation of T cells.
Cancer Biol Ther; 2004 Aug; 3(8):704. PubMed ID: 15751157
[No Abstract] [Full Text] [Related]
4. Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases.
Reeves PM; Smith SK; Olson VA; Thorne SH; Bornmann W; Damon IK; Kalman D
J Virol; 2011 Jan; 85(1):21-31. PubMed ID: 20962097
[TBL] [Abstract][Full Text] [Related]
5. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.
Lin YL; Meng Y; Jiang W; Roux B
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1664-9. PubMed ID: 23319661
[TBL] [Abstract][Full Text] [Related]
6. Abl tyrosine kinase promotes dorsal ruffles but restrains lamellipodia extension during cell spreading on fibronectin.
Jin H; Wang JY
Mol Biol Cell; 2007 Oct; 18(10):4143-54. PubMed ID: 17686996
[TBL] [Abstract][Full Text] [Related]
7. c-Abl-mediated phosphorylation of WAVE3 is required for lamellipodia formation and cell migration.
Sossey-Alaoui K; Li X; Cowell JK
J Biol Chem; 2007 Sep; 282(36):26257-65. PubMed ID: 17623672
[TBL] [Abstract][Full Text] [Related]
8. The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation.
Uemura N; Griffin JD
Blood; 2000 Nov; 96(9):3294-5. PubMed ID: 11203205
[No Abstract] [Full Text] [Related]
9. Energetic dissection of Gleevec's selectivity toward human tyrosine kinases.
Agafonov RV; Wilson C; Otten R; Buosi V; Kern D
Nat Struct Mol Biol; 2014 Oct; 21(10):848-53. PubMed ID: 25218445
[TBL] [Abstract][Full Text] [Related]
10. Eph tumour suppression: the dark side of Gleevec.
Wang JY
Nat Cell Biol; 2006 Aug; 8(8):785-6. PubMed ID: 16880809
[No Abstract] [Full Text] [Related]
11. 2-methoxyestradiol alters cell motility, migration, and adhesion.
Sattler M; Quinnan LR; Pride YB; Gramlich JL; Chu SC; Even GC; Kraeft SK; Chen LB; Salgia R
Blood; 2003 Jul; 102(1):289-96. PubMed ID: 12637335
[TBL] [Abstract][Full Text] [Related]
12. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases.
Reeves PM; Bommarius B; Lebeis S; McNulty S; Christensen J; Swimm A; Chahroudi A; Chavan R; Feinberg MB; Veach D; Bornmann W; Sherman M; Kalman D
Nat Med; 2005 Jul; 11(7):731-9. PubMed ID: 15980865
[TBL] [Abstract][Full Text] [Related]
13. Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.
Nishihara T; Miura Y; Tohyama Y; Mizutani C; Hishita T; Ichiyama S; Uchiyama T; Tohyama K
Int J Hematol; 2003 Oct; 78(3):233-40. PubMed ID: 14604282
[TBL] [Abstract][Full Text] [Related]
14. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Sims JT; Ganguly SS; Bennett H; Friend JW; Tepe J; Plattner R
PLoS One; 2013; 8(1):e55509. PubMed ID: 23383209
[TBL] [Abstract][Full Text] [Related]
15. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
[TBL] [Abstract][Full Text] [Related]
16. Abl tyrosine kinase promotes dendrogenesis by inducing actin cytoskeletal rearrangements in cooperation with Rho family small GTPases in hippocampal neurons.
Jones SB; Lu HY; Lu Q
J Neurosci; 2004 Sep; 24(39):8510-21. PubMed ID: 15456825
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.
Frasca F; Vigneri P; Vella V; Vigneri R; Wang JY
Oncogene; 2001 Jun; 20(29):3845-56. PubMed ID: 11439348
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
Dziba JM; Ain KB
J Clin Endocrinol Metab; 2004 May; 89(5):2127-35. PubMed ID: 15126530
[TBL] [Abstract][Full Text] [Related]
19. Rho-signaling pathways in chronic myelogenous leukemia.
Kuzelová K; Hrkal Z
Cardiovasc Hematol Disord Drug Targets; 2008 Dec; 8(4):261-7. PubMed ID: 19075636
[TBL] [Abstract][Full Text] [Related]
20. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
Zhang H; Trachootham D; Lu W; Carew J; Giles FJ; Keating MJ; Arlinghaus RB; Huang P
Leukemia; 2008 Jun; 22(6):1191-9. PubMed ID: 18385754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
